Description
chronic myelogenpus/
acute lymphoblastic leukemia assy-by pcr
Sample Type:2 Whole Blood
Tests Included:
Detection of the BCR-ABL fusion gene, associated with chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL)
Sample Required:
Blood sample collected from a vein in the arm.
Test Time:
Results are typically available within a few days.
Test Range Values:
The presence of the BCR-ABL fusion gene indicates the presence of the Philadelphia chromosome, a hallmark of CML and some cases of ALL.
What is the test?
The BCR-ABL test detects the presence of the BCR-ABL fusion gene, resulting from a specific chromosomal abnormality known as the Philadelphia chromosome. This abnormality is associated with chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL).
Test Procedure:
A blood sample is collected from the patient’s arm and processed to identify the BCR-ABL fusion gene using molecular techniques, such as polymerase chain reaction (PCR).
When to take the test:
The test is performed when a healthcare provider suspects CML or specific cases of ALL based on symptoms, blood cell counts, or other diagnostic findings.
Who should take the test:
Individuals with symptoms suggestive of CML, abnormal blood cell counts, or specific clinical indications may require the BCR-ABL test for diagnosis and disease monitoring.
Precautions for exceptional cases (pregnancy, etc.):
Pregnant individuals can undergo this test if necessary. Healthcare providers consider the patient’s medical history and potential risks when interpreting the results.
Frequently Asked Questions (FAQs) for BCR-ABL Test:
Q1: What is the significance of the BCR-ABL fusion gene in leukemia?
A: The BCR-ABL fusion gene results from a specific genetic mutation and leads to the production of a protein that promotes uncontrolled cell growth, contributing to the development of certain types of leukemia, particularly chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).
Q2: Is BCR-ABL testing used for disease monitoring in leukemia patients?
A: Yes, BCR-ABL testing is used to monitor the response to treatment in patients diagnosed with BCR-ABL-positive leukemias. It helps assess the effectiveness of targeted therapies, such as tyrosine kinase inhibitors, and guides treatment decisions.
Q3: Can the presence of the BCR-ABL fusion gene indicate other conditions besides leukemia?
A: The BCR-ABL fusion gene is primarily associated with leukemia, particularly CML and specific cases of ALL. In the context of leukemia diagnosis, its presence is a hallmark of these diseases. Healthcare providers interpret the results in conjunction with other clinical and laboratory findings to make a definitive diagnosis.
*Please note that specific testing protocols and guidelines may vary based on the latest recommendations from health authorities and regulatory agencies. It is essential to consult healthcare professionals and follow local testing guidelines for accurate and appropriate testing.
